[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635396":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":23,"locations":31,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"I.M. Sechenov First Moscow State Medical University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with heart failure who have been hospitalized for heart failure within the past six months",null,[12],"Other: Serial KCCQ assessments delivered via chatbot",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Serial KCCQ assessments delivered via chatbot","Eligible patients will complete the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 14-day intervals for a duration of 12 months. The KCCQ will be assessed using a chatbot delivered via Telegram Messenger, developed specifically for this study by the research team.",[9],[19],{"name":20,"affiliation":21,"role":22},"Anastasia Shchendrygina","I.M. Sechenov First Moscow State Medical University (Sechenov University)","PRINCIPAL_INVESTIGATOR",[24,28],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+79262309207","a.shchendrygina@gmail.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Svetlana Rachina","rachina_s_a@staff.sechenov.ru",[32],{"facility":21,"status":33,"city":34,"state":35,"zip":10,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Moscow","Non-US\u002FNon-Canadian","Russia","RU",{"type":39,"coordinates":40},"Point",[41,42],37.61781,55.75204,{"lat":42,"lon":41},[45,46],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},{"type":22,"investigatorFullName":20,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Associate professor","100635396","patient-reported-health-status-assessment-using-the-kccq-for-early-detection-of-heart-failure-worsening-100635396",false,"NCT07552142","Patient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening","Patient-Reported Health Status Assessment Using the Kansas City Cardiomyopathy Questionnaire for Early Detection of Heart Failure Worsening","KCCQ-WHF","Inclusion Criteria:\n\n* Established diagnosis of chronic HF with reduced, mildly reduced, or preserved ejection fraction, NYHA II-III\n* History of heart failure (HF) hospitalization within the last 6 months before enrollment, defined as the presence of dyspnea, elevated NT-proBNP ≥300 pg\u002FmL (sinus rhythm) or ≥600 pg\u002FmL (if AF), and 2 of the following: i. Rales on chest auscultation or signs of congestion on X-ray\u002FCT scan; ii. Peripheral Oedema; iii. Loop diuretics IV at admission\n* Free of signs and symptoms of congestion, defined as JVP of \\\u003C8 cm, with no orthopnea, pulmonary rales, and with trace peripheral edema or no edema.\n* Stable doses of oral loop diuretics, if prescribed\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Acute coronary syndrome, cardiac surgery, pulmonary embolism, cerebrovascular accident, ablation of atrial flutter\u002Ffibrillation, valve repair\u002Freplacement, implanted cardioverter defibrillator or urgent PCI within the last 3 months\n* Planned interventions, including major cardiac surgery (coronary artery bypass grafting, valve repair\u002Freplacement, ventricular assist device, cardiac transplantation), coronary revascularization, implantation of a cardiac device or ablation of atrial flutter\u002Ffibrillation during the study\n* Previous cardiac transplantation and candidates for heart transplantation\n* Complex congenital heart disease\n* Heart failure due to active myocarditis, pericardial constriction, known hypertrophic cardiomyopathy or cardiac amyloidosis, or uncorrected severe valvular heart disease\n* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease\n* Cirrhosis, chronic active hepatitis, or other severe hepatic disease\n* Significant drug or alcohol abuse during the last year\n* Hemodialysis\n* Infective endocarditis\n* Any active cancer","ALL","18 Years",{"count":60,"type":61},120,"ESTIMATED","12 Months","OBSERVATIONAL","This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.",[66],"Heart Failure",[68,69,70,71,72,73,74],"Kansas City Cardiomyopathy Questionnaire","Heart failure","worsening heart failure","monitoring","Cardiovascular Diseases","Heart Diseases","Congestion","2026-04-20",{"date":77,"type":78},"2026-04-27","ACTUAL",{"date":80,"type":78},"2025-10-01",{"date":82,"type":61},"2028-04-01",{"name":5,"class":6},1]